Skip to main content

McClung Barbara G's Form 4 filing

Caribou Biosciences, Inc. (CRBU) · filed Dec 8, 2021

Accession no.
0001209191-21-068582
Filed
Dec 8, 2021
Trade date
Dec 7, 2021
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market purchases total $16.5K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
McClung Barbara GCIK 0001231321Officer (Chief Legal Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 7, 2021Common StockPPurchaseAcquired+12$2.69F2+$32.28342,856Direct
Dec 7, 2021Common StockPPurchaseAcquired+6,115$2.69F2+$16,449.35348,971Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 7, 2021Common StockXIn-the-money exerciseDisposed−12$0.00$077Direct
Dec 7, 2021Common StockXIn-the-money exerciseDisposed−6,115$0.00$074,836Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)